Threshold sodium excretory and renal blood flow effects of angiotensin converting enzyme inhibition

X. Zhang, E. W. Dunham, B. G. Zimmerman

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective: To probe the potential influence of a high renal tubular level of angiotensin II on sodium reabsorption using angiotensin converting enzyme inhibitors and a non-peptide angiotensin antagonist. Methods: Systemic arterial blood pressure, renal blood flow (RBF) and electrolyte and urinary excretion were measured in anesthetized uninephrectomized Wistar rats. Captopril (n = 12), ramiprilat (n = 10) or EXP 3174 (n = 9) was infused into the renal artery in graded doses to examine whether the threshold dose that increased RBF was lower than that which increased sodium excretion rate (Na+ excretion rate). Results: Whereas ramiprilat (0.5-4 μg/kg/min intra-arterially) and EXP3174 (0.5-4 μg/kg/min intra-arterially) decreased blood pressure in all but the lowest dose of 0.5 μg/kg/min, captopril (1-8 μg/kg/min intra-arterially) did not change blood pressure except for a slight effect with the two higher doses. These three agents increased RBF to about the same degree, between 6% and 18%, which was relatively large compared with the maximal vasodilator response achievable in the kidney with acetylcholine (30-37%). Captopril given intra-arterially had a more consistent effect on Na+ excretion rate than either ramiprilat or EXP3174. An increase in Na+ excretion rate occurred with captopril ranging from 44% to 78%, whereas no significant change was obtained with the other drugs. The dose of captopril that increased RBF was the same as that which increased Na+ excretion rate. In those experiments in which ramiprilat resulted in an increase in Na+ excretion rate (five of 10 experiments), the effective dose was the same as that which increased RBF. Conclusion: When administered by the intra-arterial route, captopril was more effective in increasing Na+ excretion rate than either ramiprilat or EXP 3174. Although the threshold dose of captopril and ramiprilat required to increase Na+ excretion rate and RBF was similar, suggesting blockade of a common angiotensin II pool, there was not a good correlation between these two effects.

Original languageEnglish (US)
Pages (from-to)1413-1419
Number of pages7
JournalJournal of Hypertension
Volume13
Issue number12 I
StatePublished - Dec 1 1995

Fingerprint

Renal Circulation
Captopril
Peptidyl-Dipeptidase A
Sodium
Angiotensin II
Blood Pressure
Kidney
Angiotensins
Renal Artery
Vasodilator Agents
Angiotensin-Converting Enzyme Inhibitors
Electrolytes
Acetylcholine
ramiprilat
Wistar Rats
Arterial Pressure
EXP3174
Pharmaceutical Preparations

Keywords

  • Angiotensin antagonist
  • Angiotensin II
  • Kidney
  • Renin-angiotensin system

Cite this

Threshold sodium excretory and renal blood flow effects of angiotensin converting enzyme inhibition. / Zhang, X.; Dunham, E. W.; Zimmerman, B. G.

In: Journal of Hypertension, Vol. 13, No. 12 I, 01.12.1995, p. 1413-1419.

Research output: Contribution to journalArticle

Zhang, X, Dunham, EW & Zimmerman, BG 1995, 'Threshold sodium excretory and renal blood flow effects of angiotensin converting enzyme inhibition', Journal of Hypertension, vol. 13, no. 12 I, pp. 1413-1419.
Zhang, X. ; Dunham, E. W. ; Zimmerman, B. G. / Threshold sodium excretory and renal blood flow effects of angiotensin converting enzyme inhibition. In: Journal of Hypertension. 1995 ; Vol. 13, No. 12 I. pp. 1413-1419.
@article{fb8d4705085d4bc0993a157162707cc8,
title = "Threshold sodium excretory and renal blood flow effects of angiotensin converting enzyme inhibition",
abstract = "Objective: To probe the potential influence of a high renal tubular level of angiotensin II on sodium reabsorption using angiotensin converting enzyme inhibitors and a non-peptide angiotensin antagonist. Methods: Systemic arterial blood pressure, renal blood flow (RBF) and electrolyte and urinary excretion were measured in anesthetized uninephrectomized Wistar rats. Captopril (n = 12), ramiprilat (n = 10) or EXP 3174 (n = 9) was infused into the renal artery in graded doses to examine whether the threshold dose that increased RBF was lower than that which increased sodium excretion rate (Na+ excretion rate). Results: Whereas ramiprilat (0.5-4 μg/kg/min intra-arterially) and EXP3174 (0.5-4 μg/kg/min intra-arterially) decreased blood pressure in all but the lowest dose of 0.5 μg/kg/min, captopril (1-8 μg/kg/min intra-arterially) did not change blood pressure except for a slight effect with the two higher doses. These three agents increased RBF to about the same degree, between 6{\%} and 18{\%}, which was relatively large compared with the maximal vasodilator response achievable in the kidney with acetylcholine (30-37{\%}). Captopril given intra-arterially had a more consistent effect on Na+ excretion rate than either ramiprilat or EXP3174. An increase in Na+ excretion rate occurred with captopril ranging from 44{\%} to 78{\%}, whereas no significant change was obtained with the other drugs. The dose of captopril that increased RBF was the same as that which increased Na+ excretion rate. In those experiments in which ramiprilat resulted in an increase in Na+ excretion rate (five of 10 experiments), the effective dose was the same as that which increased RBF. Conclusion: When administered by the intra-arterial route, captopril was more effective in increasing Na+ excretion rate than either ramiprilat or EXP 3174. Although the threshold dose of captopril and ramiprilat required to increase Na+ excretion rate and RBF was similar, suggesting blockade of a common angiotensin II pool, there was not a good correlation between these two effects.",
keywords = "Angiotensin antagonist, Angiotensin II, Kidney, Renin-angiotensin system",
author = "X. Zhang and Dunham, {E. W.} and Zimmerman, {B. G.}",
year = "1995",
month = "12",
day = "1",
language = "English (US)",
volume = "13",
pages = "1413--1419",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "12 I",

}

TY - JOUR

T1 - Threshold sodium excretory and renal blood flow effects of angiotensin converting enzyme inhibition

AU - Zhang, X.

AU - Dunham, E. W.

AU - Zimmerman, B. G.

PY - 1995/12/1

Y1 - 1995/12/1

N2 - Objective: To probe the potential influence of a high renal tubular level of angiotensin II on sodium reabsorption using angiotensin converting enzyme inhibitors and a non-peptide angiotensin antagonist. Methods: Systemic arterial blood pressure, renal blood flow (RBF) and electrolyte and urinary excretion were measured in anesthetized uninephrectomized Wistar rats. Captopril (n = 12), ramiprilat (n = 10) or EXP 3174 (n = 9) was infused into the renal artery in graded doses to examine whether the threshold dose that increased RBF was lower than that which increased sodium excretion rate (Na+ excretion rate). Results: Whereas ramiprilat (0.5-4 μg/kg/min intra-arterially) and EXP3174 (0.5-4 μg/kg/min intra-arterially) decreased blood pressure in all but the lowest dose of 0.5 μg/kg/min, captopril (1-8 μg/kg/min intra-arterially) did not change blood pressure except for a slight effect with the two higher doses. These three agents increased RBF to about the same degree, between 6% and 18%, which was relatively large compared with the maximal vasodilator response achievable in the kidney with acetylcholine (30-37%). Captopril given intra-arterially had a more consistent effect on Na+ excretion rate than either ramiprilat or EXP3174. An increase in Na+ excretion rate occurred with captopril ranging from 44% to 78%, whereas no significant change was obtained with the other drugs. The dose of captopril that increased RBF was the same as that which increased Na+ excretion rate. In those experiments in which ramiprilat resulted in an increase in Na+ excretion rate (five of 10 experiments), the effective dose was the same as that which increased RBF. Conclusion: When administered by the intra-arterial route, captopril was more effective in increasing Na+ excretion rate than either ramiprilat or EXP 3174. Although the threshold dose of captopril and ramiprilat required to increase Na+ excretion rate and RBF was similar, suggesting blockade of a common angiotensin II pool, there was not a good correlation between these two effects.

AB - Objective: To probe the potential influence of a high renal tubular level of angiotensin II on sodium reabsorption using angiotensin converting enzyme inhibitors and a non-peptide angiotensin antagonist. Methods: Systemic arterial blood pressure, renal blood flow (RBF) and electrolyte and urinary excretion were measured in anesthetized uninephrectomized Wistar rats. Captopril (n = 12), ramiprilat (n = 10) or EXP 3174 (n = 9) was infused into the renal artery in graded doses to examine whether the threshold dose that increased RBF was lower than that which increased sodium excretion rate (Na+ excretion rate). Results: Whereas ramiprilat (0.5-4 μg/kg/min intra-arterially) and EXP3174 (0.5-4 μg/kg/min intra-arterially) decreased blood pressure in all but the lowest dose of 0.5 μg/kg/min, captopril (1-8 μg/kg/min intra-arterially) did not change blood pressure except for a slight effect with the two higher doses. These three agents increased RBF to about the same degree, between 6% and 18%, which was relatively large compared with the maximal vasodilator response achievable in the kidney with acetylcholine (30-37%). Captopril given intra-arterially had a more consistent effect on Na+ excretion rate than either ramiprilat or EXP3174. An increase in Na+ excretion rate occurred with captopril ranging from 44% to 78%, whereas no significant change was obtained with the other drugs. The dose of captopril that increased RBF was the same as that which increased Na+ excretion rate. In those experiments in which ramiprilat resulted in an increase in Na+ excretion rate (five of 10 experiments), the effective dose was the same as that which increased RBF. Conclusion: When administered by the intra-arterial route, captopril was more effective in increasing Na+ excretion rate than either ramiprilat or EXP 3174. Although the threshold dose of captopril and ramiprilat required to increase Na+ excretion rate and RBF was similar, suggesting blockade of a common angiotensin II pool, there was not a good correlation between these two effects.

KW - Angiotensin antagonist

KW - Angiotensin II

KW - Kidney

KW - Renin-angiotensin system

UR - http://www.scopus.com/inward/record.url?scp=0029616340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029616340&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 1413

EP - 1419

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 12 I

ER -